نتائج البحث - "Roh, Michael H."

العلاقة: Wong, Kristine S.; Jo, Vickie Y.; Lowe, Alarice C.; Faquin, William C.; Renshaw, Andrew A.; Shah, Akeesha A.; Roh, Michael H.; Stelow, Edward B.; Krane, Jeffrey F. (2020). "Malignancy risk for solitary and multiple nodules in Hürthle cell–predominant thyroid fine‐needle aspirations: A multi‐institutional study." Cancer Cytopathology (1): 68-75.; https://hdl.handle.net/2027.42/153015Test; Cancer Cytopathology; Sclabas GM, Staerkel GA, Shapiro SE, et al. Fine‐needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg. 2003; 186: 702 ‐ 709; discussion 709‐710. doi:10.1016/j.amjsurg.2003.08.015; Alaedeen DI, Khiyami A, McHenry CR. Fine‐needle aspiration biopsy specimen with a predominance of Hürthle cells: a dilemma in the management of nodular thyroid disease. Surgery. 2005; 138: 650 ‐ 656; discussion 656‐657. doi:10.1016/j.surg.2005.06.047; Elliott DD, Pitman MB, Bloom L, Faquin WC. Fine‐needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: acytomorphologic study of 139 cases with statistical analysis. Cancer. 2006; 108: 102 ‐ 109. doi:10.1002/cncr.21716; Gonzalez JL, Wang HH, Ducatman BS. Fine‐needle aspiration of Hürthle cell lesions: a cytomorphologic approach to diagnosis. Am J Clin Pathol. 1993; 100: 231 ‐ 235. doi:10.1093/ajcp/100.3.231; Kasper KA, Stewart J, Das K. Fine‐needle aspiration cytology of thyroid nodules with Hürthle cells: cytomorphologic predictors for neoplasms, improving diagnostic accuracy and overcoming pitfalls. Acta Cytol. 2014; 58: 145 ‐ 152. doi:10.1159/000358264; Renshaw AA. Hürthle cell carcinoma is a better gold standard than Hürthle cell neoplasm for fine‐needle aspiration of the thyroid: defining more consistent and specific cytologic criteria. Cancer. 2002; 96: 261 ‐ 266. doi:10.1002/cncr.10797; Yang GC, Schreiner AM, Sun W. Can abundant colloid exclude oncocytic (Hürthle cell) carcinoma in thyroid fine needle aspiration? Cytohistological correlation of 127 oncocytic (Hürthle cell) lesions. Cytopathology. 2013; 24: 185 ‐ 193. doi:10.1111/j.1365-2303.2012.00988.x; Renshaw AA, Gould EW. Impact of specific patterns on the sensitivity for follicular and Hurthle cell carcinoma in thyroid fine‐needle aspiration. Cancer Cytopathol. 2016; 124: 729 ‐ 736. doi:10.1002/cncy.21741; Wu HH, Clouse J, Ren R. Fine‐needle aspiration cytology of Hürthle cell carcinoma of the thyroid. Diagn Cytopathol. 2008; 36: 149 ‐ 154. doi:10.1002/dc.20750; Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria, and Explanatory Notes. Springer; 2018.; Park HJ, Moon JH, Yom CK, et al. Thyroid “atypia of undetermined significance” with nuclear atypia has high rates of malignancy and BRAF mutation. Cancer Cytopathol. 2014; 122: 512 ‐ 520. doi:10.1002/cncy.21411; Onder S, Firat P, Ates D. The Bethesda System For Reporting Thyroid Cytopathology: an institutional experience of the outcome of indeterminate categories. Cytopathology. 2014; 25: 177 ‐ 184. doi:10.1111/cyt.12091; Wu HH, Inman A, Cramer HM. Subclassification of “atypia of undetermined significance” in thyroid fine‐needle aspirates. Diagn Cytopathol. 2014; 42: 23 ‐ 29. doi:10.1002/dc.23052; Kim SJ, Roh J, Baek JH, et al. Risk of malignancy according to sub‐classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda System For Reporting Thyroid Cytopathology. Cytopathology. 2017; 28: 65 ‐ 73. doi:10.1111/cyt.12352; Renshaw AA. Should “atypical follicular cells” in thyroid fine‐needle aspirates be subclassified? Cancer Cytopathol. 2010; 118: 186 ‐ 189. doi:10.1002/cncy.20091; Valderrabano P, Khazai L, Thompson ZJ, et al. Cancer risk stratification of indeterminate thyroid nodules: a cytological approach. Thyroid. 2017; 27: 1277 ‐ 1284. doi:10.1089/thy.2017.0221; Sangalli G, Serio G, Zampatti C, Bellotti M, Lomuscio G. Fine needle aspiration cytology of the thyroid: a comparison of 5469 cytological and final histological diagnoses. Cytopathology. 2006; 17: 245 ‐ 250. doi:10.1111/j.1365-2303.2006.00335.x; Kelman AS, Rathan A, Leibowitz J, Burstein DE, Haber RS. Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens. Thyroid. 2001; 11: 271 ‐ 277. doi:10.1089/105072501750159714; Roh MH, Jo VY, Stelow EB, et al. The predictive value of the fine‐needle aspiration diagnosis “Suspicious for a follicular neoplasm, Hürthle cell type” in patients with Hashimoto thyroiditis. Am J Clin Pathol. 2011; 135: 139 ‐ 145. doi:10.1309/AJCP0RW2WMDUAKGK; Deandrea M, Ragazzoni F, Motta M, et al. Diagnostic value of a cytomorphological subclassification of follicular patterned thyroid lesions: a study of 927 consecutive cases with histological correlation. Thyroid. 2010; 20: 1077 ‐ 1083. doi:10.1089/thy.2010.0015; Raparia K, Min SK, Mody DR, Anton R, Amrikachi M. Clinical outcomes for “suspicious” category in thyroid fine‐needle aspiration biopsy: patient’s sex and nodule size are possible predictors of malignancy. Arch Pathol Lab Med. 2009; 133: 787 ‐ 790. doi:10.1043/1543-2165-133.5.787; Sippel RS, Elaraj DM, Khanafshar E, Kebebew E, Duh QY, Clark OH. Does the presence of additional thyroid nodules on ultrasound alter the risk of malignancy in patients with a follicular neoplasm of the thyroid? Surgery. 2007; 142: 851 ‐ 857. doi:10.1016/j.surg.2007.08.011; Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine‐needle aspiration? Diagn Cytopathol. 2006; 34: 330 ‐ 334. doi:10.1002/dc.20440; Sorrenti S, Trimboli P, Catania A, Ulisse S, De Antoni E, D’Armiento M. Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm. Thyroid. 2009; 19: 355 ‐ 360. doi:10.1089/thy.2008.0338; Kauffmann PR, Dejax C, de Latour M, Dauplat J. The meaning and predictivity of Hürthle cells in fine needle aspiration cytology for thyroid nodular disease. Eur J Surg Oncol. 2004; 30: 786 ‐ 789. doi:10.1016/j.ejso.2004.05.017; Giorgadze T, Rossi ED, Fadda G, Gupta PK, LiVolsi VA, Baloch Z. Does the fine‐needle aspiration diagnosis of “Hürthle‐cell neoplasm/follicular neoplasm with oncocytic features” denote increased risk of malignancy? Diagn Cytopathol. 2004; 31: 307 ‐ 312. doi:10.1002/dc.20132; Castro MR, Espiritu RP, Bahn RS, et al. Predictors of malignancy in patients with cytologically suspicious thyroid nodules. Thyroid. 2011; 21: 1191 ‐ 1198. doi:10.1089/thy.2011.0146; Turanli S, Pirhan Y, Ozcelik CK, Cetin A. Predictors of malignancy in patients with a thyroid nodule that contains Hürthle cells. Otolaryngol Head Neck Surg. 2011; 144: 514 ‐ 517. doi:10.1177/0194599810394052; Brito JP, Yarur AJ, Prokop LJ, McIver B, Murad MH, Montori VM. Prevalence of thyroid cancer in multinodular goiter versus single nodule: a systematic review and meta‐analysis. Thyroid. 2013; 23: 449 ‐ 455. doi:10.1089/thy.2012.0156; Canberk S, Griffin AC, Goyal A, et al. Oncocytic follicular nodules of the thyroid with or without chronic lymphocytic thyroiditis: an institutional experience. Cytojournal. 2013; 10: 2. doi:10.4103/1742-6413.106686; Mete O, Asa SL. Oncocytes, oxyphils, Hürthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules. Endocr Pathol. 2010; 21: 16 ‐ 24. doi:10.1007/s12022-009-9102-2

الإتاحة: https://doi.org/10.1002/cncy.22213Test
https://doi.org/10.1016/j.amjsurg.2003.08.015Test
https://doi.org/10.1016/j.surg.2005.06.047Test
https://doi.org/10.1002/cncr.21716Test
https://doi.org/10.1093/ajcp/100.3.231Test
https://doi.org/10.1159/000358264Test
https://doi.org/10.1002/cncr.10797Test
https://doi.org/10.1002/cncy.21741Test
https://doi.org/10.1002/dc.20750Test
https://doi.org/10.1002/cncy.21411Test